Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice Recommendation for Adults with Chronic Plaque Psoriasis
Approved by NICE for patients with severe plaque psoriasis as defined by PASI and DLQI greater than or equal to 10
Novel oral treatment that does not require regular laboratory monitoring
Recognised by NICE as an oral alternative to existing injectable biological therapies
These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).